Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B

BMC Immunology

Daming Zuo³  Zhengliang Chen⁴  Qiang Ma²  Xiaoyong Zhang³  Jia Zhou⁴  Xuan Huang³  Qintao Lai³  Liqian Chen⁴  Di Ma⁴  Zuxiong Huang¹  Ying Chen⁴ 

[1] Department of Hepatology, Affiliated Infectious Disease Hospital of Fujian Medical University, Fuzhou, China;Institute of Antibody Engineering, School of Biotechnology, Southern Medical University, Guangzhou, China;State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China;Department of Immunology, School of Basic Medicine, Southern Medical University, Guangzhou 510515, China

关键词: T cell activation;    Chronic hepatitis B;    Scavenger receptor A;   

Others  :  1209042
DOI  :  10.1186/s12865-015-0088-x

 received in 2014-09-16, accepted in 2015-03-31,  发布年份 2015

【 摘 要 】

Background

Scavenger receptor A (SRA) is expressed predominantly in phagocytic cells playing an essential role in the host immune defense against invading microorganisms. Our previous study reported the presence of SRA in a soluble form in patients with infection of hepatitis B viruses (HBV). However, the association of soluble SRA with stages of HBV infection and the immune response induced by HBV is not fully determined.

Methods

In this study, we detected soluble SRA in serum from 29 chronic hepatitis B (CHB) patients, 28 chronic HBV carriers in the immune tolerant (IT) stage, 33 in the HBeAg-negative inactive carrier (IC) stage, and 22 healthy controls (HCs), respectively. We further analyzed the correlation of detected soluble SRA to inflammation and serum viral load. In addition, we investigated the regulatory role of soluble SRA in T cell activation, especially in CD8⁺ T cell response to HBV peptide.

Results

We demonstrated that Median levels of serum soluble SRA in CHB and IT patients were significantly higher than those of IC patients and HCs. Additionally, the concentrations of soluble SRA were negatively correlated with alanine transaminase levels in CHB patients. We also found that serum concentration of SRA was decreased during telbivudine treatment. Expressed SRA extracellular domain suppressed HBV core peptide-stimulated interferon-γ and tumor necrosis factor-α production in CD8⁺ T cells, and it bound to T cells in a higher frequency in CHB patients than in HCs. Furthermore, we observed that naïve human T cells stimulated by anti-CD3 and CD28 antibodies in the presence of the recombinant SRA protein had reduced activation and proliferation.

Conclusion

In summary, we determined the level of soluble SRA in different stages of CHB patients. SRA might inhibit T cell proliferation and activation as a soluble form. These results not only revealed a previously unknown feature of soluble SRA in CHB patients but also provided broad understanding of SRA in T cell activation.

【 授权许可】

   
2015 Chen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373:582-92.
• [2]Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009; 49 Suppl 5:13-21.
• [3]Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS et al.. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000; 191:1269-80.
• [4]Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012; 61:1754-64.
• [5]Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010; 184:287-95.
• [6]Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al.. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003; 77:68-76.
• [7]Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al.. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007; 81:4215-25.
• [8]Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J et al.. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest. 2008; 118:1835-45.
• [9]Larrubia JR, Benito-Martinez S, Miquel J, Calvino M, Sanz-de-Villalobos E, Gonzalez-Praetorius A et al.. Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1(+)/CD127(−) HCV-specific CD8(+) cells targeting the virus in chronic hepatitis C virus infection. Cell Immunol. 2011; 269:104-14.
• [10]Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010; 138:682-93.
• [11]Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L et al.. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011; 53:1494-503.
• [12]Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y et al.. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One. 2012; 7: Article ID e47648
• [13]Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N et al.. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology. 2009; 137:1289-300.
• [14]Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol. 2002; 14:123-8.
• [15]Hansen B, Arteta B, Smedsrod B. The physiological scavenger receptor function of hepatic sinusoidal endothelial and Kupffer cells is independent of scavenger receptor class A type I and II. Mol Cell Biochem. 2002; 240:1-8.
• [16]Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K et al.. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997; 386:292-6.
• [17]Facciponte JG, Wang XY, Subjeck JR. Hsp110 and Grp170, members of the Hsp70 superfamily, bind to scavenger receptor-A and scavenger receptor expressed by endothelial cells-I. Eur J Immunol. 2007; 37:2268-79.
• [18]Guo C, Yi H, Yu X, Hu F, Zuo D, Subjeck JR et al.. Absence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response. Immunol Cell Biol. 2012; 90:101-8.
• [19]Wang XY, Facciponte J, Chen X, Subjeck JR, Repasky EA. Scavenger receptor-A negatively regulates antitumor immunity. Cancer Res. 2007; 67:4996-5002.
• [20]Yi H, Yu X, Gao P, Wang Y, Baek SH, Chen X et al.. Pattern recognition scavenger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood. 2009; 113:5819-28.
• [21]Yi H, Zuo D, Yu X, Hu F, Manjili MH, Chen Z et al.. Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell. J Mol Med. 2012; 90:413-26.
• [22]Haisma HJ, Boesjes M, Beerens AM, van der Strate BW, Curiel DT, Pluddemann A et al.. Scavenger receptor A: a new route for adenovirus 5. Mol Pharm. 2009; 6:366-74.
• [23]Zuo D, Yu X, Guo C, Wang H, Qian J, Yi H et al.. Scavenger receptor A restrains T-cell activation and protects against concanavalin A-induced hepatic injury. Hepatology. 2013; 57:228-38.
• [24]Hampton RY, Golenbock DT, Penman M, Krieger M, Raetz CR. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature. 1991; 352:342-4.
• [25]Wang H, Kadlecek TA, Au-Yeung BB, Goodfellow HE, Hsu LY, Freedman TS et al.. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol. 2010; 2:a002279.
• [26]Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S et al.. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012; 143:963-73.
• [27]Loggi E, Bihl FK, Cursaro C, Granieri C, Galli S, Brodosi L et al.. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One. 2013; 8: Article ID e65327
• [28]Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF et al.. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011; 55:522-8.
• [29]Laukkanen J, Lehtolainen P, Gough PJ, Greaves DR, Gordon S, Yla-Herttuala S. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modified low-density lipoprotein degradation and foam-cell formation in macrophages. Circulation. 2000; 101:1091-6.
• [30]Jalkanen J, Leppanen P, Pajusola K, Narvanen O, Mahonen A, Vahakangas E et al.. Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Molecular therapy: the journal of the American Society of Gene Therapy. 2003; 8:903-10.
• [31]Jozefowski S, Kobzik L. Scavenger receptor A mediates H2O2 production and suppression of IL-12 release in murine macrophages. J Leukoc Biol. 2004; 76:1066-74.
• [32]Jozefowski S, Arredouani M, Sulahian T, Kobzik L. Disparate Regulation and Function of the Class A Scavenger Receptors SR-AI/II and MARCO. J Immunol. 2005; 175:8032-41.
• [33]Fulton WB, Reeves RH, Takeya M, De Maio A. A quantitative trait Loci analysis to map genes involved in lipopolysaccharide-induced inflammatory response: identification of macrophage scavenger receptor 1 as a candidate gene. J Immunol. 2006; 176:3767-73.
• [34]Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol. 2006; 87:1439-49.
• [35]Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol. 2003; 39:115-24.
• [36]Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG et al.. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005; 41:771-8.
• [37]Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001; 2:66-70. BioMed Central Full Text
• [38]Arredouani MS, Franco F, Imrich A, Fedulov A, Lu X, Perkins D et al.. Scavenger Receptors SR-AI/II and MARCO limit pulmonary dendritic cell migration and allergic airway inflammation. J Immunol. 2007; 178:5912-20.
• [39]Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507-39.
• [40]Lai Q, Ma S, Ge J, Huang Z, Huang X, Jiang X et al.. TCRgammadelta(+)CD4(−)CD8(−) T Cells Suppress the CD8(+) T-Cell Response to Hepatitis B Virus Peptides, and Are Associated with Viral Control in Chronic Hepatitis B. PLoS One. 2014; 9: Article ID e88475
• [41]Liang M, Ma S, Hu X, Zhou B, Zhang J, Chen J et al.. Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol J. 2011; 8:69. BioMed Central Full Text